Compare Blackstone Inc (BX) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Blackstone Inc vs DexCom, Inc. — how do they compare? Blackstone Inc trades at $126.21 (market cap $152.15B), while DexCom, Inc. trades at $76.3 (market cap $28.60B). The key difference: Blackstone Inc is far larger — about 5.3× DexCom, Inc.'s market cap, and Blackstone Inc pays a 3.99% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| BX | DXCM | |
|---|---|---|
Market Cap | $152.15B | $28.60B |
Sector | Financials | Health |
52-Week High | $188.68 | $89.53 |
52-Week Low | $102.12 | $54.84 |
Dividend Yield | 3.99% | — |
Enterprise Value | — | $27.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Blackstone (BX) trades at $122.06, down 0.83% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 24.27% net income margin highlight robust profitability, while a $5.34 billion AI infrastructure deal with Williams underscores strategic growth. The stock faces resistance near $123 with support at $121.
Outlook remains positive given consistent earnings outperformance and institutional bullishness, though valuation multiples like a P/E of 31.29 pose risks if growth slows. Key opportunities include AI-driven investments, while macroeconomic volatility and high leverage are concerns.
DXCM trades at $76.35, up 1.85% today, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 17.93% net income margin and consistent earnings beats. Recent regulatory approvals for G7 15-day CGM in Canada and pediatric clearance for Stelo OTC system highlight growth catalysts. Revenue growth accelerated to $4.66 billion in 2025, up from $4.0 billion in 2024.
DXCM presents a compelling growth story with expanding CGM market access and strong analyst support (80% buy ratings). Key risks include GLP-1 adoption impact on core market and execution of Type 2 non-insulin patient expansion. The stock trades at a premium valuation (P/E 32.76) but offers upside to consensus target of $83.78. Near-term focus on Q2 2026 earnings release July 30.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Blackstone Inc
Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
